KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Free Cash Flow (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Free Cash Flow for 16 consecutive years, with $999000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 1507.04% year-over-year to $999000.0, compared with a TTM value of $2.1 million through Sep 2025, up 155.06%, and an annual FY2024 reading of $1.2 million, up 105.07% over the prior year.
  • Free Cash Flow was $999000.0 for Q3 2025 at TherapeuticsMD, up from $381000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $48.0 million in Q4 2021 and bottomed at -$38.4 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$3.5 million, with a median of -$229000.0 recorded in 2024.
  • The sharpest move saw Free Cash Flow crashed 134.03% in 2023, then soared 1507.04% in 2025.
  • Year by year, Free Cash Flow stood at $48.0 million in 2021, then tumbled by 37.01% to $30.2 million in 2022, then tumbled by 116.4% to -$5.0 million in 2023, then soared by 100.34% to $17000.0 in 2024, then skyrocketed by 5776.47% to $999000.0 in 2025.
  • Business Quant data shows Free Cash Flow for TXMD at $999000.0 in Q3 2025, $381000.0 in Q2 2025, and $699000.0 in Q1 2025.